ArticleInfection and immunity2017
Identification of Mycobacterial RplJ/L10 and RpsA/S1 Proteins as Novel Targets for CD4
Open access · bronzeAbstract read
In one paragraph
Article in Infection and immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Ribosomal protein RPSA is a promising target for the prevention of Streptococcus suis serotype 2.Applied microbiology and biotechnology · 2026Article
- In silico design of a multiantigenic and multiepitope chimeric protein as a vaccine candidate againstFrontiers in cellular and infection microbiology · 2026Article
- Iron-restricted Mycobacterium tuberculosis exports pathogenicity factors packed in extracellular vesicles.PloS one · 2025Article
- Intranasal Immunization with Nasal Immuno-Inducible Sequence-Fused Antigens Elicits Antigen-Specific Antibody Production.International journal of molecular sciences · 2024Article
- Boosting Immunogenicity of a RecombinantBiomedicines · 2024Article
- Vaccines against Tuberculosis: Where Are We Now?Vaccines · 2023Review
- HigB1 Toxin inFrontiers in microbiology · 2021Article
- Exploiting Pre-Existing CD4Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Generation of IL-3-Secreting CD4ImmunoHorizons · 2019Article
- Identification of Mycobacterial Ribosomal Proteins as Targets for CD4Infection and immunity · 2018Article
- Personalized vaccinology: A review.Vaccine · 2018Review
- Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity.Cell chemical biology · 2018Article
- A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune Models forFrontiers in immunology · 2018Review
- Transcriptome Analysis of Mycobacteria-Specific CD4Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Tuberculosis vaccines - perspectives from the NIH/NIAID Mycobacteria vaccine testing program.Current opinion in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Alison J JohnsonDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Steven C KennedyDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Cecilia S Lindestam ArlehamnDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Michael F GoldbergDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Neeraj K SainiDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Jiayong XuDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Sinu PaulDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Subray S HegdeDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
John S BlanchardDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
John ChanDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
William R JacobsDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Alessandro SetteDepartment of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Steven A PorcelliDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA steven.porcelli@einstein.yu.edu.
Albert Einstein College of Medicine · USLa Jolla Institute for Immunology · USHoward Hughes Medical Institute · US
Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI STEVEN C. ALMO · 1985 to 2026
$111.2M"The Tuberculous Granuloma"P01AI063537 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI JACOBS, WILLIAM ROBERT · 2005 to 2015
$15.7MMolecular Genetic Analysis of Mycobacterium TuberculosisR37AI026170 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI WILLIAM Robert JACOBS · 2004 to 2026
$7.7MBacterial N-Acetyltransferases: Resistance to RegulationR01AI060899 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI BLANCHARD, JOHN S · 2004 to 2018
$7.7MVaccines for Extensively Drug Resistant TuberculosisR01AI098925 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JACOBS, WILLIAM ROBERT · 2012 to 2016
$5.8MMOLECULAR PATHOGENESIS OF INFECTIOUS DISEASEST32AI007506 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2012
$3.7MConstruction of safe and effective live tuberculosis vaccinesR01AI093649 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PORCELLI, STEVEN A · 2011 to 2015
$2.1MDefining the Correlates of Bactericidal Immunity in TuberculosisR21AI092448 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI PORCELLI, STEVEN A · 2011 to 2012
$457kHoward Hughes Medical InstituteNCI NIH HHS P30 CA013330NIAID NIH HHS HHSN272200900044CNIAID NIH HHS P01 AI063537NIAID NIH HHS R01 AI060899NIAID NIH HHS R01 AI093649NIAID NIH HHS R01 AI098925NIAID NIH HHS R21 AI092448NIAID NIH HHS R37 AI026170NIAID NIH HHS T32 AI007506
Abstract
Tuberculosis (TB) due to
Indexed as
Amino Acid SequenceAnimalsAntigens, BacterialBacterial ProteinsCD4-Positive T-LymphocytesCytokinesDisease Models, AnimalEpitope MappingEpitopes, T-LymphocyteFemaleHistocompatibility Antigens Class IIImmunizationMiceMycobacteriumPeptidesRibosomal ProteinsAntigens, BacterialBacterial ProteinsCytokinesEpitopes, T-LymphocyteHistocompatibility Antigens Class IIPeptidesRibosomal ProteinsantigenepitoperibosomeT cellstuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.